Lista de obras - Susan O'Brien - Dominio Público Uruguay

10 years of progress in chronic myelogenous leukemia.

artículo científico publicado en 2012

2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome

artículo científico publicado en 2005

5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen

artículo científico publicado en 2009

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

artículo científico publicado en 2015

A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

artículo científico publicado en 2015

A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia

artículo científico publicado en 2004

A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia ⬇️

artículo científico publicado el 20 de agosto de 2010

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

artículo científico publicado en 2010

A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia

artículo científico publicado en 2009

A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2014

A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes

artículo científico publicado en 2002

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia

artículo científico publicado en 2010

A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies

artículo científico publicado en 2008

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.

artículo científico publicado en 2016

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2017

A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia

artículo científico publicado en 2014

A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia

artículo científico publicado en 2018

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.

artículo científico publicado en 2007

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors

artículo científico publicado en 2018

A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia

artículo científico publicado en 2012

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2017

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

artículo científico publicado en 2003

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens

artículo científico publicado en 2006

A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia

artículo científico publicado en 2011

Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells

artículo científico publicado en 2015

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

artículo científico publicado en 2015

Accelerated and blastic phases of chronic myelogenous leukemia

artículo científico publicado en 2004

Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia

scientific article published on 23 July 2013

Activity of alemtuzumab in patients with CD52-positive acute leukemia

scientific article published on 01 June 2006

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

artículo científico publicado en 2005

Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates

artículo científico publicado en 2013

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis

artículo científico publicado en 2013

Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes

artículo científico publicado en 2005

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia

artículo científico publicado en 2003

Adult acute lymphoblastic leukemia: concepts and strategies

artículo científico publicado en 2010

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center

artículo científico publicado en 2005

Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemot

artículo científico publicado en 2009

Adverse prognostic features in chronic lymphocytic leukemia

artículo científico

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

artículo científico publicado en 2003

Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

artículo científico publicado en 2010

Alemtuzumab in CLL and other lymphoid neoplasms

artículo científico publicado en 2006

Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay.

artículo científico publicado en 2004

Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis

artículo científico publicado en 2014

Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia

artículo científico publicado en 2003

An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation

artículo científico publicado en 2007

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders

artículo científico publicado en 2003

Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes

artículo científico publicado en 2016

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

artículo científico publicado en 2012

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase

artículo científico publicado en 2003

Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen

artículo científico publicado en 2010

Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia

artículo científico

Aspergillus pseudomembranous necrotizing tracheitis

artículo científico publicado en 2012

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

artículo científico publicado en 2013

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center

artículo científico publicado en 2007

Atypical chronic lymphocytic leukemia with polyglandular autoimmune endocrinopathy type II: a complex profile

artículo científico publicado en 2014

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

artículo científico publicado en 2014

Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy

artículo científico publicado en 2011

Aurora-A kinase nuclear expression in chronic lymphocytic leukemia.

artículo científico publicado en 2008

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib

artículo científico publicado en 2016

BCR inhibitor failure in CLL: an unmet need

artículo científico publicado en 2016

BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias

artículo científico publicado en 2008

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy

artículo científico publicado en 2009

Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival

artículo científico publicado en 2002

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

artículo científico publicado en 2015

Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?

artículo científico publicado en 2011

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia ⬇️

artículo científico publicado el 29 de noviembre de 2010

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

artículo científico publicado en 2015

CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia

artículo científico publicado en 2002

Cause of death in patients with lower-risk myelodysplastic syndrome

artículo científico publicado en 2010

Central nervous system Richter's transformation and parvovirus B19 infection

artículo científico publicado en 2013

Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies

artículo científico publicado en 2010

Central nervous system relapse in adults with acute lymphoblastic leukemia

artículo científico publicado en 2002

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations

artículo científico publicado en 2018

Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

artículo científico publicado en 2008

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy

artículo científico publicado en 2010

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

artículo científico publicado en 2008

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment

artículo científico publicado en 2009

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials ⬇️

artículo científico publicado en 2017

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

artículo científico publicado en 2009

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

artículo científico publicado en 2010

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

artículo científico publicado en 2005

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

artículo científico publicado en 2006

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage

scientific article published on 11 October 2018

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

artículo científico publicado en 2007

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase

artículo científico publicado en 2003

Chronic Myelogenous Leukemia, Version 1.2014

artículo científico publicado en 2013

Chronic lymphocytic leukaemia

article

Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients

artículo científico publicado en 2008

Chronic lymphocytic leukemia: current and emerging treatment approaches

artículo científico publicado en 2006

Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment

artículo científico publicado en 2005

Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy

artículo científico publicado en 2002

Chronic myelogenous leukemia, version 1.2015.

artículo científico publicado en 2014

Chronic myelogenous leukemia: a review and update of therapeutic strategies

artículo científico publicado en 2003

Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

artículo científico publicado en 2016

Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease

scientific article published on 01 December 2003

Circulating CD33 and its clinical value in acute leukemia

artículo científico publicado en 2010

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

artículo científico publicado en 2009

Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia

artículo científico publicado en 2010

Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia

artículo científico publicado en 2009

Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia

artículo científico publicado en 2008

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial

scientific article published on 13 August 2018

Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

artículo científico publicado en 2016

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction

artículo científico publicado en 2015

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis

artículo científico publicado en 2014

Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens

artículo científico publicado en 2017

Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML).

artículo científico publicado en 2016

Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

artículo científico publicado en 2010

Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation

artículo científico publicado en 2006

Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma

artículo científico publicado en 2004

Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease

scientific article published on 20 March 2006

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

artículo científico publicado en 2006

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

artículo científico publicado en 2016

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

artículo científico publicado en 2015

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

scientific article published on 01 December 2018

Combinatorial targeting of the macropinocytotic pathway in leukemia and lymphoma cells

artículo científico publicado en 2008

Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen

artículo científico publicado en 2002

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

artículo científico publicado en 2003

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens

artículo científico publicado en 2015

Comprehensive craniospinal radiation for controlling central nervous system leukemia

artículo científico publicado en 2014

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

artículo científico publicado en 2015

Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia

artículo científico publicado en 2017

Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex

artículo científico publicado en 2017

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia

artículo científico publicado en 2014

Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL).

artículo científico publicado en 2010

Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3.

artículo científico publicado en 2011

Current and emerging treatment options in chronic myeloid leukemia

artículo científico publicado en 2007

Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia

artículo científico publicado en 2010

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

artículo científico publicado en 2011

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

artículo científico publicado en 2008

Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia

artículo científico publicado en 2010

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

artículo científico publicado en 2009

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

artículo científico publicado en 2006

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience

artículo científico publicado en 2009

Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome

artículo científico publicado en 2013

Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration ⬇️

artículo científico publicado el 24 de agosto de 2010

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

scientific article published on 15 April 2009

Design, development, and validation of a high-throughput drug-screening assay for targeting of human leukemia

artículo científico publicado en 2013

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

artículo científico publicado en 2013

Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.

artículo científico publicado en 2009

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia

artículo científico publicado en 2016

Discontinuation of imatinib therapy after achieving a molecular response

artículo científico publicado en 2004

Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia

artículo científico publicado en 2015

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

artículo científico publicado en 2002

Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.

artículo científico publicado en 2007

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

artículo científico publicado en 2017

Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

scientific article published on 20 October 2018

Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation.

artículo científico publicado en 2016

Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure

artículo científico publicado en 2009

EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience

artículo científico publicado en 2012

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

artículo científico publicado en 2016

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

artículo científico publicado en 2013

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

artículo científico publicado en 2005

Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States

artículo científico publicado en 2016

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin

artículo científico publicado en 2008

Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies

artículo científico

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

artículo científico publicado en 2003

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

scientific article published on 01 May 2019

Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.

artículo científico publicado en 2018

Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.

artículo científico publicado en 2018

Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia

scientific article published on 24 November 2020

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

artículo científico publicado en 2002

Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia

artículo científico publicado en 2013

Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia

artículo científico publicado en 2012

Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia

artículo científico publicado en 2012

Emerging information on the use of rituximab in chronic lymphocytic leukemia

artículo científico publicado en 2002

Emerging therapy for the treatment of acute lymphoblastic leukemia

artículo científico publicado en 2010

End points to establish the efficacy of new agents in the treatment of acute leukemia.

artículo científico publicado en 2006

Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia

artículo científico publicado en 2008

Epigenetics of acute lymphocytic leukemia

artículo científico publicado en 2009

Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia

artículo científico publicado en 2010

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

artículo científico publicado en 2014

Eradication of minimal residual disease in hairy cell leukemia

artículo científico publicado en 2006

Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2004

Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia

artículo científico

Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

artículo científico publicado en 2015

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials

artículo científico publicado en 2018

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

artículo científico publicado en 2003

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

artículo científico publicado en 2002

Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia

artículo científico publicado en 2011

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

artículo científico publicado en 2017

Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients

artículo científico publicado en 2015

Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge

artículo científico publicado en 2014

FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia

artículo científico publicado en 2014

Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia

artículo científico publicado en 2017

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast

artículo científico publicado en 2009

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

artículo científico publicado en 2008

Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome

artículo científico publicado en 2002

Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin

artículo científico publicado en 2013

Feasibility of therapy with hypomethylating agents in patients with renal insufficiency

artículo científico publicado en 2010

Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

artículo científico publicado en 2019

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2015

Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen

artículo científico publicado en 2016

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

artículo científico publicado en 2010

Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia

artículo científico publicado en 2004

Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia

artículo científico publicado en 2013

Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia

artículo científico publicado en 2015

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

artículo científico publicado en 2011

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

artículo científico publicado en 2015

Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years

artículo científico publicado en 2009

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit

artículo científico publicado en 2003

Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

artículo científico publicado en 2011

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

artículo científico publicado en 2011

Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia

artículo científico publicado en 2016

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

artículo científico publicado en 2014

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

artículo científico publicado en 2003

Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes

artículo científico publicado en 2012

Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia

artículo científico publicado en 2004

Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia.

artículo científico publicado en 2018

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

artículo científico publicado en 2013

Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy

artículo científico publicado en 2010

High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome

artículo científico publicado en 2015

High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia

artículo científico publicado en 2010

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

artículo científico publicado en 2003

High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia

artículo científico publicado en 2012

Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.

artículo científico publicado en 2006

Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval

scientific article published on 20 June 2013

Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma

artículo científico publicado en 2017

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis

artículo científico publicado en 2016

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial

artículo científico publicado en 2020

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia

artículo científico publicado en 2002

Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia

artículo científico publicado en 2017

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

artículo científico publicado en 2013

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

artículo científico publicado en 2016

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

artículo científico publicado en 2016

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

artículo científico publicado en 2014

Ibrutinib: a paradigm shift in management of CLL.

artículo científico publicado en 2014

Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology

artículo científico publicado en 2007

Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction

artículo científico publicado en 2010

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

artículo científico publicado en 2002

Imatinib mesylate causes hypopigmentation in the skin

artículo científico publicado en 2003

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

artículo científico publicado en 2008

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

artículo científico publicado en 2002

Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.

artículo científico publicado en 2002

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

artículo científico publicado en 2003

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

artículo científico publicado en 2002

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia

artículo científico publicado en 2004

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia

artículo científico publicado en 2004

Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors

artículo científico publicado en 2007

Immune defects in patients with chronic lymphocytic leukemia

artículo científico publicado en 2005

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin

artículo científico publicado en 2010

Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression

artículo científico publicado en 2010

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

artículo científico publicado en 2016

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

artículo científico publicado en 2017

Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2016

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

artículo científico publicado en 2017

Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia

artículo científico publicado en 2011

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

artículo científico publicado en 2012

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

scientific article published on 23 July 2015

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

artículo científico publicado en 2019

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

artículo científico publicado en 2014

Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia

artículo científico publicado en 2013

Initial treatment of CLL: integrating biology and functional status

artículo científico publicado en 2015

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

artículo científico publicado en 2016

Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas

artículo científico

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl

scientific article published on 15 April 2019

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

artículo científico publicado en 2018

Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia

artículo científico

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study

artículo científico publicado en 2019

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

artículo científico publicado en 2012

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

artículo científico publicado en 2010

Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986

artículo científico publicado en 2005

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

artículo científico publicado en 2016

Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy

artículo científico publicado en 2004

Investigational immunotherapeutics for B-cell malignancies

artículo científico publicado en 2010

Investigational strategies in chronic myelogenous leukemia

artículo científico publicado en 2004

JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms ⬇️

artículo científico publicado el 13 de agosto de 2010

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors

artículo científico publicado en 2008

Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

artículo científico publicado en 2014

LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients

artículo científico publicado en 2011

Late extramedullary recurrence of adult onset Burkitt's lymphoma mimicking peritoneal carcinomatosis

artículo científico publicado en 2013

Late relapses in acute myeloid leukemia: analysis of characteristics and outcome

artículo científico publicado en 2010

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

artículo científico publicado en 2011

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

artículo científico publicado en 2008

Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia

artículo científico publicado en 2013

Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant

artículo científico publicado en 2013

Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib

artículo científico publicado en 2017

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.

artículo científico publicado en 2018

Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.

artículo científico publicado en 2016

Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

artículo científico publicado en 2016

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2015

Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes

artículo científico publicado en 2011

Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival

artículo científico publicado en 2017

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

artículo científico publicado en 2006

Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical tr

artículo científico publicado en 2015

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

artículo científico publicado en 2016

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

artículo científico publicado en 2009

Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib

artículo científico publicado en 2017

Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib

artículo científico publicado en 2010

Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia

artículo científico publicado en 2020

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

artículo científico publicado en 2014

Long-term results of frontline dasatinib in chronic myeloid leukemia

scientific article published on 30 January 2020

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

scientific article published on 14 April 2008

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

artículo científico publicado en 2004

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.

artículo científico publicado en 2015

Maintenance therapy for B-chronic lymphocytic leukemia

artículo científico publicado en 2011

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

artículo científico publicado en 2011

Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.

artículo científico publicado en 2007

Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience

artículo científico publicado en 2004

Mature T-cell leukemias

artículo científico publicado en 2005

Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia

artículo científico publicado en 2006

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

artículo científico publicado en 2015

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

artículo científico publicado en 2013

Molecular differences between small and large cells in patients with chronic lymphocytic leukemia

artículo científico publicado en 2003

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

artículo científico publicado en 2005

Monoclonal antibodies in the treatment of leukemia

artículo científico publicado en 2005

Monoclonal antibody combinations in CLL: evolving strategies

artículo científico publicado en 2006

Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia

artículo científico publicado en 2009

Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia

artículo científico publicado en 2012

Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity

artículo científico publicado en 2008

Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia

artículo científico publicado en 2011

Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor

artículo científico publicado en 2014

Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia

artículo científico publicado en 2008

Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia

artículo científico publicado en 2013

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

artículo científico publicado en 2003

NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia ⬇️

artículo científico publicado el 1 de febrero de 2011

Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia

artículo científico publicado en 2007

New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia

artículo científico publicado en 2007

New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia

artículo científico

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

artículo científico publicado en 2006

New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance

artículo científico publicado en 2007

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

artículo científico publicado en 2009

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

artículo científico publicado en 2006

Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome

artículo científico publicado en 2011

Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia

artículo científico publicado en 2012

Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies

artículo científico publicado en 2013

Novel therapies for relapsed acute lymphoblastic leukemia

artículo científico publicado en 2009

Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial

artículo científico publicado en 2015

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

artículo científico publicado en 2016

Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies

artículo científico publicado en 2006

Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

artículo científico publicado en 2010

Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma

scientific article published on 29 December 2008

Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia

artículo científico publicado en 2013

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia

artículo científico publicado en 2016

Outcome of adults with acute lymphocytic leukemia after second salvage therapy

artículo científico publicado en 2008

Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission

artículo científico publicado en 2010

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

artículo científico publicado en 2009

Outcome of patients with acute myelogenous leukemia after second salvage therapy

artículo científico publicado en 2005

Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy

artículo científico publicado en 2011

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium

artículo científico publicado en 2014

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

artículo científico publicado en 2010

Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression

artículo científico publicado en 2017

Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy

artículo científico publicado en 2010

Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma

artículo científico publicado en 2004

Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure

artículo científico publicado en 2015

Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma

artículo científico publicado en 2017

Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion

artículo científico publicado en 2014

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

artículo científico publicado en 2015

Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity

artículo científico publicado en 2016

Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure

artículo científico publicado en 2014

Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis

artículo científico publicado en 2019

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).

artículo científico publicado en 2016

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

artículo científico publicado en 2013

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

artículo científico publicado en 2016

Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia

artículo científico publicado en 2009

Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies

artículo científico publicado en 2005

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

artículo científico publicado en 2007

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

artículo científico publicado en 2010

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

artículo científico publicado en 2006

Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

artículo científico publicado en 2020

Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia

artículo científico publicado en 2010

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

artículo científico publicado en 2003

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

artículo científico publicado en 2011

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse

artículo científico publicado en 2009

Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia

artículo científico publicado en 2013

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome

artículo científico publicado en 2009

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

artículo científico publicado en 2003

Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia

artículo científico publicado en 2005

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes

artículo científico publicado en 2005

Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies

artículo científico publicado en 2015

Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia

artículo científico publicado en 2005

Phase I study of oral topotecan in hematological malignancies ⬇️

artículo científico publicado el 15 de septiembre de 2003

Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia

artículo científico publicado en 2012

Phase I trial of nelarabine in indolent leukemias

artículo científico publicado en 2008

Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome

artículo científico publicado en 2013

Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia

artículo científico publicado en 2008

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

artículo científico publicado en 2010

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.

artículo científico publicado en 2007

Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia

artículo científico publicado en 2013

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

artículo científico publicado en 2003

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms

artículo científico publicado en 2009

Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia

artículo científico publicado en 2003

Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis

artículo científico publicado en 2008

Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders

artículo científico publicado en 2002

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

artículo científico publicado en 2012

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.

artículo científico publicado en 2007

Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

artículo científico publicado en 2014

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia

artículo científico publicado en 2006

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia

artículo científico publicado en 2002

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

artículo científico publicado en 2003

Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia

artículo científico publicado en 2017

Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

artículo científico publicado en 2014

Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose c

Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors

artículo científico publicado en 2019

Philadelphia-positive acute lymphoblastic leukemia: current treatment options

artículo científico

Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia

artículo científico publicado en 2007

Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase

artículo científico publicado en 2011

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

artículo científico publicado en 2006

Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia.

artículo científico publicado en 2006

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

article

Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study

artículo científico publicado en 2015

Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor

artículo científico publicado en 2016

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies

artículo científico publicado en 2014

Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid

artículo científico publicado en 2005

Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2017

Prediction model for mortality after intracranial hemorrhage in patients with leukemia

artículo científico publicado en 2011

Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

artículo científico publicado en 2003

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

artículo científico publicado en 2010

Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2010

Pregnancy among patients with chronic myeloid leukemia treated with imatinib

artículo científico publicado en 2006

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.

artículo científico publicado en 2018

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

artículo científico publicado en 2017

Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine

artículo científico publicado en 2012

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

artículo científico publicado en 2015

Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib

artículo científico publicado en 2011

Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia

artículo científico publicado en 2016

Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease

artículo científico publicado en 2016

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin

artículo científico publicado en 2019

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

artículo científico publicado en 2007

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia

artículo científico publicado en 2008

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

artículo científico publicado en 2003

Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia

artículo científico publicado en 2016

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia

artículo científico publicado en 2013

Progress in acute myeloid leukemia

artículo científico publicado en 2015

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

artículo científico publicado en 2014

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

artículo científico publicado en 2008

Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome

artículo científico publicado en 2009

Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia

artículo científico publicado en 2006

Proteomics-based prediction of clinical response in acute myeloid leukemia

artículo científico publicado en 2009

Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.

artículo científico publicado en 2003

Questions regarding frontline therapy of acute myeloid leukemia

artículo científico publicado en 2010

Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.

artículo científico publicado en 2003

Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay

artículo científico publicado en 2012

Recent advances in de novo CD5+ diffuse large B cell lymphoma

artículo científico

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

artículo científico publicado en 2015

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

artículo científico publicado en 2008

Reply to myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.

artículo científico publicado en 2013

Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia

artículo científico publicado en 2008

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

artículo científico publicado en 2003

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

artículo científico publicado en 2004

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

artículo científico publicado en 2006

Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations

artículo científico publicado en 2010

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

artículo científico publicado en 2009

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

artículo científico publicado en 2003

Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome

artículo científico publicado en 2004

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

artículo científico publicado en 2003

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

artículo científico publicado en 2013

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

artículo científico publicado en 2018

Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia

artículo científico publicado en 2008

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

artículo científico publicado en 2003

Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine

artículo científico publicado en 2013

Rituximab in relapsed or refractory hairy cell leukemia

artículo científico publicado en 2003

Role of leukemia cell invadosome in extramedullary infiltration

scientific article published on 27 July 2009

Role of the tumor microenvironment in mature B-cell lymphoid malignancies

artículo científico publicado en 2016

Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article published on September 2011

Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial

artículo científico publicado en 2017

STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosis

artículo científico publicado en 2014

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

artículo científico publicado en 2003

Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

artículo científico publicado en 2014

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

artículo científico publicado en 2014

Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia

artículo científico publicado en 2014

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

artículo científico publicado en 2017

Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia

artículo científico publicado en 2015

Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

artículo científico publicado en 2014

Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate

artículo científico publicado en 2008

Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia

artículo científico publicado en 2010

Sequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphoma

artículo científico publicado en 2013

Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells

artículo científico publicado en 2013

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

artículo científico publicado en 2013

Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response

artículo científico publicado en 2009

Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy

artículo científico publicado en 2005

Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission

artículo científico publicado en 2017

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

artículo científico publicado en 2009

Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications

artículo científico publicado en 2011

Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome

artículo científico publicado en 2010

Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials

artículo científico publicado en 2013

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia

artículo científico publicado en 2002

Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia

artículo científico publicado en 2003

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

artículo científico publicado en 2018

Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.

artículo científico publicado en 2006

Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease?

artículo científico publicado en 2012

Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal

artículo científico publicado en 2006

Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells

artículo científico publicado en 2014

Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome

artículo científico publicado en 2002

Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate

artículo científico publicado en 2005

Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications

artículo científico publicado en 2003

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

artículo científico publicado en 2009

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience

artículo científico publicado en 2007

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls

artículo científico publicado en 2004

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience

artículo científico publicado en 2005

Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia

artículo científico publicado en 2009

Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy

artículo científico publicado en 2010

T-cell prolymphocytic leukemia: a single-institution experience

scientific article published on 01 November 2005

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens

artículo científico publicado en 2017

Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia

artículo científico publicado en 2013

Targeted therapy for chronic lymphocytic leukemia

scientific article published on 27 January 2009

Targeted therapy in chronic myeloid leukemia

artículo científico publicado en 2008

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

artículo científico publicado en 2013

Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens

artículo científico publicado en 2015

Targeting neuropilin-1 in human leukemia and lymphoma

artículo científico publicado en 2011

Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia

artículo científico publicado en 2004

Thalidomide therapy for myelofibrosis with myeloid metaplasia

scientific article published on 01 May 2006

The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia

artículo científico publicado en 2013

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

artículo científico publicado en 2011

The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells

artículo científico publicado en 2013

The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab

artículo científico publicado en 2017

The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure

artículo científico publicado en 2013

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

artículo científico publicado en 2011

The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience

artículo científico publicado en 2015

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells

artículo científico publicado en 2008

The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease

artículo científico publicado en 2002

The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

artículo científico publicado en 2011

The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia

artículo científico publicado en 2004

The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy ⬇️

artículo científico publicado el 23 de octubre de 2010

The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy

artículo científico publicado en 2010

The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy

artículo científico publicado en 2005

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival

scientific article published on 19 November 2019

The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia

artículo científico publicado en 2015

The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation

artículo científico publicado en 2014

The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment

artículo científico

The great imitator: systemic nocardiosis mimicking Richter's transformation in relapsed chronic lymphocytic leukemia

artículo científico publicado en 2010

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?

artículo científico publicado en 2009

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

artículo científico publicado en 2007

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

artículo científico publicado en 2011

The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia

artículo científico publicado en 2011

The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients

artículo científico publicado en 2008

The role of gemtuzumab ozogamicin in acute leukaemia therapy

artículo científico publicado en 2006

The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

artículo científico publicado en 2004

The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells

artículo científico publicado en 2010

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

scientific article published on 03 September 2009

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years

artículo científico publicado en 2008

Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens

artículo científico publicado en 2009

Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice

artículo científico publicado en 2015

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

artículo científico publicado en 2015

Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia

artículo científico publicado en 2003

Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis

scientific article published on 21 September 2020

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

artículo científico publicado en 2003

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside

artículo científico publicado en 2003

Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.

artículo científico publicado en 2002

Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.

artículo científico publicado en 2014

Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia

scientific article published on 10 February 2019

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

artículo científico publicado en 2012

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase

artículo científico publicado en 2013

Ubiquitin–proteasome system profiling in acute leukemias and its clinical relevance ⬇️

artículo científico publicado el 15 de octubre de 2010

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome

artículo científico publicado en 2007

Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience

artículo científico publicado en 2003

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

artículo científico publicado en 2007

Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy

artículo científico publicado en 2012

Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome

artículo científico publicado en 2004

p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy

artículo científico publicado en 2009

β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia

artículo científico publicado en 2015

Lista de obras de Susan O'Brien

10 years of progress in chronic myelogenous leukemia.

2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome

5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia

A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia ⬇️

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia

A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia

A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia

A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia

A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors

A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens

A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia

Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

Accelerated and blastic phases of chronic myelogenous leukemia

Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia

Activity of alemtuzumab in patients with CD52-positive acute leukemia

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis

Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia

Adult acute lymphoblastic leukemia: concepts and strategies

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center

Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemot

Adverse prognostic features in chronic lymphocytic leukemia

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

Alemtuzumab in CLL and other lymphoid neoplasms

Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay.

Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis

Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia

An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders

Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase

Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen

Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia

Aspergillus pseudomembranous necrotizing tracheitis

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center

Atypical chronic lymphocytic leukemia with polyglandular autoimmune endocrinopathy type II: a complex profile

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy

Aurora-A kinase nuclear expression in chronic lymphocytic leukemia.

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib

BCR inhibitor failure in CLL: an unmet need

BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy

Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia ⬇️

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia

Cause of death in patients with lower-risk myelodysplastic syndrome

Central nervous system Richter's transformation and parvovirus B19 infection

Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies

Central nervous system relapse in adults with acute lymphoblastic leukemia

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations

Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials ⬇️